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Introduction and Objectives
Hepatitis C virus (HCV) infection is a leading cause of chronic
liver disease with life threatening sequelae such as end-stage
liver cirrhosis and liver cancer. It is estimated that the infectiongms | | Market Uptake of Pegylated Interferons for the Treatment of Hepatitis C in Europe
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annually causes about 86,000 deaths, 1.2 million disability
adjusted life years (DALYs), and ¼ of the liver transplants in
the WHO European region [1].
Presently, only antiviral drugs can prevent the progression to
severe liver disease. Pegylated interferons combined with
ribavirin are considered as current state-of-the-art treatment.
Objective of this investigation was to assess the market uptake
of these drugs across Europe in order to find out whether there
is unequal access to optimised therapy.
Material and Methods
We used IMS launch and sales data (April 2000 to December
2005) for peginterferons and ribavirin for 21 countries of the
WHO European region [2]. Market uptake was investigated by
comparing the development of country-specific sales rates. For
market access analysis, we converted sales figures into
numbers of treated patients and related those to country-
specific hepatitis C prevalence.
To convert sales figures into patient figures, the amount of
active pharmaceutical ingredients (API) sold was divided by
average total patient doses (ATPD), derived by a probability
tree-based calculation algorithm accounting for genotype
distribution, early stopping rules, body weight, unscheduled
treatment stops and dose reductions
Ntotal=APIPegIFNa-2a/ATPDPegIFNa-2a+APIPegIFNa-
2b/ATPDPegIFNa-2b
For more concise result presentation the 21 included countries
were aggregated into four categories:
EU founding members (1957): Belgium, France,
Germany, Italy and Netherlands;
Countries joining EU before 2000: Austria (1995),
Denmark (1973), Finland (1995), Greece (1981),
Republic of Ireland (1973), Spain (1986), Sweden and
UK (1973)
Countries joining EU after 2000: Czech Republic
(2004), Hungary (2004), Poland (2004) and Romania
(2007);
EU non-member states: Norway, Russia, Switzerland
and Turkey.
Results
Market launch and market uptake of the investigated drugs
differed considerably across countries. The earliest, most rapid
and highest increases in sales rates were observed in the EU
founding member states, followed by countries that joined the
EU before 2000, countries that joined the EU after 2000, and
EU non-member states. Most new EU member states showed a
noticeable increase in sales after joining the EU.
Market access analysis yielded that until end of 2005, about
308 000 patients were treated with peginterferon in the 21
countries. Treatment rates differed across Europe. The number
of patients ever treated with peginterferon per 100 prevalent
cases ranged from 16 in France to less than one in Romania,
Poland, Greece and Russia.
Discussion
Peginterferon market uptake and prevalence adjusted
treatment rates were found to vary considerably across 21
countries in the WHO European region suggesting unequal
access to optimised therapy. Poor market access was especially
common in low-resource countries. Besides budget restrictions,
national surveillance and prevention policy should be
considered as explanations for market access variation.
Although our results allowed for the ranking of countries in
order of market access, no final conclusions on over- orgms | | Market Uptake of Pegylated Interferons for the Treatment of Hepatitis C in Europe
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undertreatment can be drawn, because the number of patients
who really require antiviral treatment is unknown. Further
research based on pan-European decision models is
recommended to determine the fraction of not yet successfully
treated but treatable patients among those ever diagnosed with
HCV.
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